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  EVIDENCE-BASED ANSWER 
For proximal saphenous vein thrombosis, anticoagulation is more effective than venous ligation (with or without 
stripping) in preventing deep venous thrombosis (DVT) and pulmonary embolus (PE) (strength of 
recommendation [SOR]: C, qualitative systematic review of primarily case series). 
For patients with superficial venous thrombophlebitis (SVTP) distal to the saphenous vein of the thigh, 
tenoxicam (a nonsteroidal anti-inflammatory agent [NSAID]) and low-molecular-weight heparin are similarly 
effective for reducing extension and subsequent DVT when administered along with compression therapy 
(SOR: B, 1 randomized controlled trial). Oral or topical NSAIDs, topical heparin, and topical nitroglycerin all 
alleviate symptoms and speed resolution of SVTP caused by infusion catheters (SOR: B, smaller, occasionally 
conflicting randomized trials). 
  EVIDENCE SUMMARY 
Superficial thrombophlebitis refers to erythema, pain, induration, and other findings of inflammation in 
superficial veins, usually due to infection or thrombosis. Typically, SVTP is localized problem, but some lower-
extremity SVTP is associated with increased risk of DVT and PE, particularly the long saphenous vein. This 
review will not address thrombosis in the superficial femoral vein, a portion of the deep venous system, which 
requires full DVT therapy.1 
Since saphenous vein thrombosis above the knee is associated with DVT and PE, 1 systematic review looked 
at papers comparing anticoagulation (IV heparin followed by 6 weeks to 6 months of warfarin) with surgical 
ligation of the saphenous vein (either alone or combined with vein stripping or with vein stripping and perforator 
ligation).1 The review included primarily case series with widely varying protocols. According to the authors, the 
data “suggests that medical management with anticoagulants is somewhat superior” to surgery for preventing 
DVT and PE. However, the fewest extensions of SVTP occurred when vein ligation was combined with 
stripping of the thrombosed vein and interruption of perforators. 
In a more recent trial, patients randomized to subcutaneous heparin at 12,500 units twice daily for a week 
followed by 10,000 units twice daily had fewer vascular complications of proximal saphenous vein thrombosis 
than those receiving heparin at 5000 units twice daily (6/30 in the low-dose group and 1/30 in the high-dose 
group; P<.05; number needed to treat [NNT]=6).2 There were no bleeding complications in either group. 
One large double-blind randomized controlled trial compared tenoxicam (an NSAID available in Canada, 
similar to piroxicam), enoxaparin (Lovenox), and placebo for 8 to 12 days in 427 patients with SVTP of the leg 
measuring 5 cm or more.3 Patients were also treated with compression hose. Patients who required immediate 
anticoagulation or venous ligation were excluded. Within 3 months, 35% of patients taking placebo developed 
an extension or recurrence of their SVTP or a DVT, compared with 16% to 17% of treated patients (NNT=6). 
There was no significant difference in outcome between subcutaneous enoxaparin at fixed (40 mg/d) or 
adjusted doses (1.5 mg/kg), or 20 mg/d oral tenoxicam. In a small randomized trial (n=40), intramuscular 
defibrotide provided better symptom resolution than low-dose heparin for patients with uncomplicated SVTP of 
the leg.4 
For infusion-related SVTP, a randomized controlled trial of 120 patients found both oral and topical diclofenac 
effective in reducing symptoms (NNT=3), although oral diclofenac had significantly more gastrointestinal side 
effects (number needed to harm=3 for dyspepsia).5 Two double-blind trials of topical heparin showed it to be 
superior to placebo in reducing symptoms and speeding healing.6,7 
In the larger study (n=126), 44% of patients treated with 1000 IU/g heparin gel 3 times a day were symptom-
free at 1 week, compared with 26% on placebo (NNT=6).7 A randomized trial of infusion-related SVTP (n=100) 
found that 2% nitroglycerin gel eliminated pain in 50 hours vs 72 hours with topical heparin (P<.05).8 A smaller, 
underpowered double-blind trial of topical heparin, piroxicam gel, and placebo (22 to 24 patients in each 
treatment arm) failed to find efficacy with either therapy.9 
  RECOMMENDATION FROM OTHERS 
For SVTP of the leg that does not include the proximal saphenous vein, Up To Date recommends compression 
and oral NSAIDs, noting that NSAIDs are inexpensive, help with symptom control, and appear comparable to 
low-molecular-weight heparin in limiting complications.10 
CLINICAL COMMENTARY: 
Those with symptoms in the thigh need closer follow-up, 
more aggressive therapy 
 
James  L.  Greenwald,  MD 
SUNY Upstate Medical University,Syracuse, NY 
Patients with a red, swollen, painful extremity are commonly encountered in my practice. I see this 
among patients with venous stasis due to obesity, aging, and varicosities. I find ready access to a 
D-dimer blood test and a venous Doppler can help me rule out DVT. I end up treating many of these 
patients with both an NSAID and an antistaphylococcal antibiotic, because of the lack of certainty in 
differentiating superficial phlebitis from cellulitis. 
Upper extremity phlebitis is less common. It can occur in a delayed fashion several days after a 
patient has received intravenous therapy. The characteristic on exam is a knotty, red, ropey painful 
structure correlating to the course of the basilic or cephalic vein. 
This review is helpful to me; it reinforces that the patients I see with symptoms in the thigh need 
closer follow-up and more aggressive therapy with anticoagulation, no matter what the Doppler 
shows. I usually hold off on anticoagulating other patients until they show no improvement with a 
trial of the NSAIDs and compression. Topical heparin and nitroglycerin gel are therapies new to me 
and appear worth looking into for the patient who is not improving. In a quick search for topical 
heparin, I could not find a US source, and it is not used locally. 
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